United Therapeutics (UTHR) Misses Q2 EPS, Revenues Beat
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $536.59 -2.7%
Revenue Growth %: +1.5%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +1.5%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of $460.67 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Pfizer reaffirms 2026 guidance after CFO transition news
- Goldman Sachs Starts Chagee Holdings (CHA) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
